CLYMbenzinga

Climb Bio Entered Technology Transfer And Exclusive License Agreement With Beijing Mabworks Biotech Co.; Climb Obligated To Pay Mabworks $9M Upfront And Up To $30M On Milestones, With Total Up To $832M Upon Achievement Of Certain Milestones For All Licens

Summary

No summary available.

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on January 10, 2025 by benzinga